191 related articles for article (PubMed ID: 21823612)
1. Cell death induced by the Jak2 inhibitor, G6, correlates with cleavage of vimentin filaments.
Majumder A; Kirabo A; Karrupiah K; Tsuda S; Caldwell-Busby J; Cardounel AJ; Keseru GM; Sayeski PP
Biochemistry; 2011 Sep; 50(36):7774-86. PubMed ID: 21823612
[TBL] [Abstract][Full Text] [Related]
2. The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo.
Kirabo A; Embury J; Kiss R; Polgár T; Gali M; Majumder A; Bisht KS; Cogle CR; Keseru GM; Sayeski PP
J Biol Chem; 2011 Feb; 286(6):4280-91. PubMed ID: 21127060
[TBL] [Abstract][Full Text] [Related]
3. Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core.
Majumder A; Govindasamy L; Magis A; Kiss R; Polgár T; Baskin R; Allan RW; Agbandje-McKenna M; Reuther GW; Keseru GM; Bisht KS; Sayeski PP
J Biol Chem; 2010 Oct; 285(41):31399-407. PubMed ID: 20667821
[TBL] [Abstract][Full Text] [Related]
4. The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.
Kirabo A; Park SO; Majumder A; Gali M; Reinhard MK; Wamsley HL; Zhao ZJ; Cogle CR; Bisht KS; Keserü GM; Sayeski PP
Neoplasia; 2011 Nov; 13(11):1058-68. PubMed ID: 22131881
[TBL] [Abstract][Full Text] [Related]
5. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
Kirabo A; Park SO; Wamsley HL; Gali M; Baskin R; Reinhard MK; Zhao ZJ; Bisht KS; Keserű GM; Cogle CR; Sayeski PP
Am J Pathol; 2012 Sep; 181(3):858-65. PubMed ID: 22796437
[TBL] [Abstract][Full Text] [Related]
6. The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.
Baskin R; Park SO; Keserű GM; Bisht KS; Wamsley HL; Sayeski PP
PLoS One; 2014; 9(8):e105568. PubMed ID: 25162558
[TBL] [Abstract][Full Text] [Related]
7. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
8. Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth.
Sayyah J; Magis A; Ostrov DA; Allan RW; Braylan RC; Sayeski PP
Mol Cancer Ther; 2008 Aug; 7(8):2308-18. PubMed ID: 18723478
[TBL] [Abstract][Full Text] [Related]
9. A46, a benzothiophene-derived compound, suppresses Jak2-mediated pathologic cell growth.
Majumder A; Magis AT; Park SO; Figueroa NC; Baskin R; Kirabo A; Allan RW; Zhao ZJ; Bisht KS; Keseru GM; Sayeski PP
Exp Hematol; 2012 Jan; 40(1):22-34. PubMed ID: 22019628
[TBL] [Abstract][Full Text] [Related]
10. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
Quintás-Cardama A; Manshouri T; Estrov Z; Harris D; Zhang Y; Gaikwad A; Kantarjian HM; Verstovsek S
Invest New Drugs; 2011 Oct; 29(5):818-26. PubMed ID: 20372971
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening.
Kiss R; Polgár T; Kirabo A; Sayyah J; Figueroa NC; List AF; Sokol L; Zuckerman KS; Gali M; Bisht KS; Sayeski PP; Keseru GM
Bioorg Med Chem Lett; 2009 Jul; 19(13):3598-601. PubMed ID: 19447617
[TBL] [Abstract][Full Text] [Related]
12. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
[TBL] [Abstract][Full Text] [Related]
13. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
Verstovsek S; Manshouri T; Quintás-Cardama A; Harris D; Cortes J; Giles FJ; Kantarjian H; Priebe W; Estrov Z
Clin Cancer Res; 2008 Feb; 14(3):788-96. PubMed ID: 18245540
[TBL] [Abstract][Full Text] [Related]
14. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
[TBL] [Abstract][Full Text] [Related]
15. JAK2 inhibition in JAK2
Dahlström J; Xia C; Xing X; Yuan X; Björkholm M; Xu D
Biochem Biophys Res Commun; 2020 Jun; 527(2):425-431. PubMed ID: 32334833
[TBL] [Abstract][Full Text] [Related]
16. Curcumin induces apoptosis in JAK2-mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways.
Petiti J; Rosso V; Lo Iacono M; Panuzzo C; Calabrese C; Signorino E; Pironi L; Cartellà A; Bracco E; Pergolizzi B; Beltramo T; Fava C; Cilloni D
J Cell Mol Med; 2019 Jun; 23(6):4349-4357. PubMed ID: 31033209
[TBL] [Abstract][Full Text] [Related]
17. The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells.
Bongartz H; Hessenkemper W; Müller C; Fensky M; Fritsch J; Mandel K; Behrmann I; Haan C; Fischer T; Feller SM; Schaper F
Cell Signal; 2017 Jul; 35():37-47. PubMed ID: 28365441
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
Fiskus W; Verstovsek S; Manshouri T; Rao R; Balusu R; Venkannagari S; Rao NN; Ha K; Smith JE; Hembruff SL; Abhyankar S; McGuirk J; Bhalla KN
Clin Cancer Res; 2011 Dec; 17(23):7347-58. PubMed ID: 21976548
[TBL] [Abstract][Full Text] [Related]
19. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.
Tyner JW; Bumm TG; Deininger J; Wood L; Aichberger KJ; Loriaux MM; Druker BJ; Burns CJ; Fantino E; Deininger MW
Blood; 2010 Jun; 115(25):5232-40. PubMed ID: 20385788
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel SAR properties of the Jak2 small molecule inhibitor G6: significance of the para-hydroxyl orientation.
Baskin R; Gali M; Park SO; Zhao ZJ; Keseru GM; Bisht KS; Sayeski PP
Bioorg Med Chem Lett; 2012 Feb; 22(3):1402-7. PubMed ID: 22227213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
